

SWOG NCORP Research Base Clinical Trials Active Studies

| Study # | Study Title | Activation | Accrual | Follow-up (from Reg Date) | Participating Sites |
|--|---|----------------|----------------------------|--------------------------------|---------------------|
| Cancer Care Delivery Research Committee | | | | | |
| S1703 | Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer | July 2018 | 299 of 1320 23% | 6 years from Step 2 rando date | NCTN and NCORP |
| S1912CD | A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) | July 2021 | 113 of 326 35% | 1 year | NCORP Only |
| S2108CD | A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy | August 2022 | 613 of 1182 52% | 2 years | NCORP Only |
| Cancer Survivorship Committee | | | | | |
| S1501 | Prospective Evaluation of Carvedilol vs No treatment in Prevention of Cardiac Dysfunction in Patients with Metastatic HER-2+ Breast Cancer | September 2017 | 300 of 817 37% | 2 years | NCTN and NCORP |
| Palliative and End of Life Care Committee | | | | | |
| | Concepts in development | | | | |
| Prevention and Epidemiology Committee | | | | | |
| S1823 | A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors | June 2020 | 822 of 956 86% | 3 years | NCTN and NCORP |
| S1904 | Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE) | September 2020 | 321 of 415 77% | 5 years | Limited institution |
| Symptom Control and Quality of Life Committee | | | | | |
| S1600 | A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes | February 2019 | 198 of 200 99% | 3 years (post-cystectomy date) | NCTN and NCORP |
| S2010 | A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN) | January 2023 | 93 of 540 17% | 1.5 years | NCTN and NCORP |
| S2013 | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | August 2021 | 1434 of 2062 70% | 1 year | NCTN and NCORP |
| S2205 | Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy | March 2023 | 33 of 777 4% | 1 year | Limited institution |

Accrual as of October 3, 2023

SWOG NCORP Research Base Clinical Trials Completed Accrual in the Past Year and/or Participants in Active Follow-up

| Study # | Study Title | Activation/ Closure | Accrual | Follow-up Length from Reg Date | Participating Sites |
|--|---|---|-----------------|-----------------------------------|---------------------|
| Prevention and Epidemiology Committee | | | | | |
| S0820 | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) | March 2013 Closed June 2023 | 354 of 389 | 8 years | NCTN and NCORP |
| Symptom Control and Quality of Life Committee | | | | | |
| S1614 | Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors | July 2021 Closed Nov 2022 | 4 of 444 | 2 years | NCTN and NCORP |
| S1714 | A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients | March 2019 Closed Nov 2021 | 1336 of 1336 | 3 years | NCTN and NCORP |

Questions? Contact cancercontrolquestion@crab.org